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Hypertension and inflammation are physiologically inter-related.1 In observational epidemiological studies, 
raised inflammatory biomarkers such as hsCRP (high sensi-
tivity C-reactive protein) and IL (interleukin)-6 correlate with 
increased blood pressure2–4 and left ventricular dysfunction,5 
and predict the future development of hypertension,6 heart 
failure,5 and major adverse cardiovascular events.2 Yet, the 
pathophysiologic mechanisms through which inflammation 
and elevated blood pressure interact, and their causal relation-
ships, remain uncertain. Preclinical evidence suggests that el-
evated blood pressure is associated with a proinflammatory 
state mediated, in part, by cytokines, such as IL-1β, that alter 
endothelial, immune, and central nervous system responses 
potentiating the development of hypertension.1 For example, 
IL-1β is increased in the kidneys of mice with angiotensin 
II–induced hypertension,7 and activation of IL-1 receptor 1 
enhances renal sodium transporter activity resulting in salt re-
tention.8 In mouse models genetic deletion of IL-1 receptor 1,9 
pharmacological blockade of IL-1 signaling,10 and adminis-
tration of an IL-1β neutralizing antibody therapy11 have been 
demonstrated to reduce blood pressure. Downstream of IL-1, 
IL-6, and CRP are implicated in the development of hyper-
tension through angiotensin II12–14 and central nervous sys-
tem-mediated T-cell activation15 and vascular inflammation.1 
Immune cell infiltration and their release of inflammatory 
cytokines like IL-1β have not only been associated with blood 
pressure elevation but also with end-organ damage associated 
with hypertension.16 Despite this evidence, the effect of thera-
pies that specifically target inflammation on blood pressure is 
largely unknown.
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Abstract—While hypertension and inflammation are physiologically inter-related, the effect of therapies that specifically 
target inflammation on blood pressure is uncertain. The recent CANTOS (Canakinumab Anti-inflammatory Thrombosis 
Outcomes Study) afforded the opportunity to test whether IL (interleukin)-1β inhibition would reduce blood pressure, 
prevent incident hypertension, and modify relationships between hypertension and cardiovascular events. CANTOS 
randomized 10 061 patients with prior myocardial infarction and hsCRP (high sensitivity C-reactive protein) ≥2 mg/L 
to canakinumab 50 mg, 150 mg, 300 mg, or placebo. A total of 9549 trial participants had blood pressure recordings 
during follow-up; of these, 80% had a preexisting diagnosis of hypertension. In patients without baseline hypertension, 
rates of incident hypertension were 23.4, 26.6, and 28.1 per 100-person years for the lowest to highest baseline tertiles of 
hsCRP (P>0.2). In all participants random allocation to canakinumab did not reduce blood pressure (P>0.2) or incident 
hypertension during the follow-up period (hazard ratio, 0.96 [0.85–1.08], P>0.2). IL-1β inhibition with canakinumab 
reduces major adverse cardiovascular event rates. These analyses suggest that the mechanisms underlying this benefit are 
not related to changes in blood pressure or incident hypertension.
Clinical Trial Registration—URL: https://clinicaltrials.gov. Unique identifier: NCT01327846.  (Hypertension. 
2020;75:477-482. DOI: 10.1161/HYPERTENSIONAHA.119.13642.) • Online Data Supplement
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In the recent CANTOS (Canakinumab Anti-inflammatory 
Thrombosis Outcome Study), canakinumab—a fully human 
monoclonal antibody targeting IL-1β—significantly reduced 
rates of recurrent cardiovascular events17 and hospitaliza-
tion for heart failure18 in patients with a history of myocar-
dial infarction and a persistent proinflammatory response. 
Furthermore, while lipid levels did not change in CANTOS, 
the magnitude of cardiovascular benefit associated with 
canakinumab was related directly to the magnitude of in-
flammation inhibition achieved as detected by on-treatment 
reductions in hsCRP and IL-6.19,20 Per protocol, all CANTOS 
participants had blood pressure systematically measured be-
fore randomization and throughout trial follow-up. CANTOS 
thus afforded the unique opportunity to test formally whether 
IL-1β inhibition reduces blood pressure, prevents the devel-
opment of incident hypertension, or modifies relationships be-
tween hypertension and cardiovascular events.
Methods
The data from the study is not available to other researchers.
Study Design and Participants
CANTOS was a randomized, double-blind placebo-controlled trial 
that evaluated 3 doses of canakinumab (50, 150, or 300 mg) admin-
istered subcutaneously once every 3 months as compared with 
matching subcutaneous placebo for the prevention of major adverse 
atherosclerotic events.17,21 Between April 28, 2011, and March 3, 
2014, CANTOS enrolled 10 061 patients with a history of myocardial 
infarction and concentrations of hsCRP of 2 mg/L or greater from 
over 1000 clinical sites in 39 countries. The study excluded patients 
with a history of chronic or recurrent infections, previous malignancy 
other than basal cell skin carcinoma, a suspected or known immu-
nocompromised state, or a history of (or high risk for) tuberculosis 
or HIV-related disease, and those using systemic anti-inflammatory 
treatments. All participants provided written informed consent to par-
ticipate in the trial, which was monitored by an independent data and 
safety monitoring board.
Procedures
Clinical history including cardiovascular risk factors and a preex-
isting diagnosis of hypertension was documented by enrolling physi-
cian before randomization. A diagnosis of incident hypertension was 
made in patients with no prior history of hypertension and a blood 
pressure of >140/90 during follow-up.
Investigators were instructed to record resting, seated blood pres-
sure in triplicate after the subject had been sitting for at least 5 min-
utes with back supported and both feet placed on the floor before drug 
administration at baseline and 3, 6, and 12 months using an appropri-
ately sized blood pressure cuff with a validated automated device or a 
manual sphygmomanometer. Blood pressure for each visit represents 
the mean of triplicate readings rounded to the nearest integer for sys-
tolic and diastolic measurements.
Blood samples were obtained from all trial participants in placebo 
and canakinumab groups at randomization and at 3 months before re-
peat canakinumab (or placebo) injection.19 Samples were assayed for 
hsCRP and samples from selected sites assayed for IL-6 concentra-
tions in a central laboratory as previously described.19,20
Outcomes
The primary end point of CANTOS was a composite of adjudicated 
recurrent myocardial infarction, stroke, or cardiovascular mortality. 
The key prespecified secondary cardiovascular end points included 
these events as well as adjudicated episodes of hospitalization 
for unstable angina requiring urgent coronary revascularization. 
Additional major end points adjudicated by the trial end point com-
mittee included cardiovascular mortality, cancer mortality,22 heart 
failure hospitalization,18 and all-cause mortality. Median follow-up 
was 3.7 years.
Statistical Analysis
For the current analyses, study participants were divided into 4 quar-
tiles according to systolic blood pressure at study enrolment (base-
line). χ2 tests were used to assess for significant differences between 
these quartiles for categorical variables, and Wilcoxon rank-sum tests 
for continuous variables. Cox proportional-hazard models stratified 
according to time since the index myocardial infarction and trial part 
were used to evaluate whether increasing levels of hsCRP associated 
with incident hypertension during trial follow-up in patients with no 
preexisting diagnosis of hypertension and to estimate relative hazards 
for major adverse cardiovascular events, myocardial infarction, cor-
onary revascularization, stroke, heart failure hospitalization, and all-
cause mortality in treatment groups as compared with those allocated 
placebo in all study participants. Analyses compared the time to clin-
ical event and adjusted for characteristics known to influence hsCRP, 
including age, sex, body mass index, LDL (low-density lipoprotein)-
cholesterol, and diabetes mellitus.
The trial is registered.
Role of the Funding Source
The trial was sponsored by Novartis Pharmaceuticals. The sponsor 
was responsible for data collection. The corresponding author had 
full access to all study data and was responsible for the decision to 
submit for publication.
Results
A total of 9549 of the 10 061 patients randomized in CANTOS 
had blood pressure data available at baseline and at 3 months. 
At enrolment, a preexisting diagnosis of hypertension was 
documented in 79.6% of patients with a population median 
blood pressure of 130/79. Stratified by quartile of base-
line systolic blood pressure (quartiles 1–4: <120, 120–129, 
130–140, and >140 mm Hg) the upper quartile was older with 
higher lipid levels (total, LDL and HDL [high-density lipo-
protein] cholesterol, and triglycerides) and higher rates of 
diabetes mellitus, hypertension, stroke, and antihypertensive 
therapy (Table 1). In contrast, smoking was more common in 
the lowest quartile of baseline systolic blood pressure, as was 
a prior diagnosis of heart failure and ST-segment–elevation 
myocardial infarction (compared to non–ST-segment–eleva-
tion myocardial infarction, Table 1).
Baseline concentrations of the inflammatory markers 
hsCRP and IL-6 were similar across quartiles of systolic blood 
pressure at baseline (Table 1). In patients without a preexisting 
diagnosis of hypertension, increased baseline hsCRP associated 
with modestly higher rates of incident hypertension during fol-
low-up, but this effect was not statistically significant (hsCRP 
tertile 1, 23.4 per 100 person-years [21.1–25.9]; tertile 2, 26.6 
[24.1–29.4]; tertile 3, 28.1 [25.4–31.0], P>0.2, Figure 1).
In the complete study group, random allocation to 
canakinumab as compared to placebo did not alter recorded 
blood pressure between baseline and the 3-, 6-, or 12-month 
visits overall or individually at the 50, 150, or 300 mg doses 
of active therapy (all P>0.2, Figure 2, and Figure S1 in the 
online-only Data Supplement). In analyses limited to those 
with normal blood pressure at trial entry, canakinumab as 
compared to placebo did not reduce the rate of new hyper-
tension diagnoses (hazard ratio, 0.96 [0.85–1.08], P>0.2). 
Furthermore, no reduction in blood pressure was identified in 
patients randomly allocated to canakinumab who achieved a 
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greater than median reduction in inflammation as assessed by 
on-treatment concentrations of hsCRP and IL-6 (Table 2).
As previously published, random allocation to canakinumab 
resulted in a significant reduction in the composite primary end 
point of nonfatal myocardial infarction, nonfatal stroke, or car-
diovascular mortality.17 As would be anticipated, when stratified 
by baseline systolic blood pressure, major adverse cardiovas-
cular events, recurrent myocardial infarction, coronary revas-
cularization, stroke, and mortality were more frequent among 
trial participants with increasing levels of baseline systolic 
blood pressure (Figure 3). Although formal tests for interaction 
were not significant, in patients with a systolic blood pressure 
of ≥130 mm Hg and baseline, allocation to canakinumab was 
associated with an absolute risk reduction of 3.4% compared to 
1.8% in patients with a baseline systolic blood pressure <130 
mm Hg (Figure 3). These differences may, however, be due to 
play of chance. No significant benefit of canakinumab on stroke 
was observed at any quartile of blood pressure.
Discussion
These analyses of the randomized, double-blind, placebo-con-
trolled CANTOS trial are inconsistent with prior evidence in 
that in patients with normal blood pressure, those with raised 
hsCRP did not have increased rates of incident hypertension. 
Per protocol patients with a hsCRP of <2 mg/L were excluded 
from trial entry and as such the truncated range of hsCRP 
levels may contribute to this finding. As anticipated, higher 
levels of baseline blood pressure in CANTOS associated 
Table 1. Patient Demographics Stratified by Quartile of Baseline Systolic BP
Characteristic Quartile 1 Quartile 2 Quartile 3 Quartile 4
Number 2431 2487 2661 2481
Systolic BP, median (min–max), mm Hg 112 (79–119) 124 (120–129) 135 (130–140) 148 (141–200)
Age, y 59.00 (52.00–66.00) 60.00 (53.00–66.00) 62.00 (55.00–69.00) 64.00 (58.00–70.00)
Female sex, n (%) 631 (25.96) 613 (24.65) 680 (25.55) 663 (26.72)
White race, n (%) 1827 (75.25) 1968 (79.16) 2149 (80.88) 2091 (84.35)
Current smoking, n (%) 664 (27.31) 595 (23.92) 577 (21.68) 530 (21.36)
Median body mass index (IQR) 29.00 (25.73–33.03) 29.75 (26.55–33.64) 30.09 (26.72–34.10) 30.28 (27.13–34.35)
Baseline diagnosis of hypertension, n (%) 1680 (69.11) 1900 (76.40) 2212 (83.13) 2215 (89.28)
Diabetes mellitus, n (%) 869 (35.75) 960 (38.60) 1121 (42.13) 1107 (44.62)
Qualifying myocardial infarction, n (%)
  STEMI 1391 (57.22) 1355 (54.48) 1459 (54.83) 1276 (51.43)
  Non-STEMI 745 (30.65) 837 (33.66) 899 (33.78) 903 (36.40)
  Unknown type or missing data 295 (12.13) 295 (11.86) 303 (11.39) 302 (12.17)
History of stroke, n (%) 115 (4.73) 110 (4.42) 124 (4.66%) 155 (6.25)
History of PCI, n (%) 1691 (69.59) 1673 (67.30) 1678 (63.08) 1668 (67.23)
History of CABG, n (%) 305 (12.55) 335 (13.48) 343 (12.89) 427 (17.21)
History of congestive heart failure, n (%) 584 (24.02) 533 (21.43) 555 (20.86) 501 (20.19)
Lipid-lowering therapy, n (%) 2292 (94.40) 2325 (93.60) 2472 (92.97) 2307 (93.02)
Statin, n (%) 2240 (92.26) 2277 (91.67) 2402 (90.33) 2238 (90.24)
β-blocker, n (%) 2008 (82.87) 2029 (81.72) 2189 (82.42) 2084 (84.20)
Calcium channel antagonist, n (%) 342 (14.09) 489 (19.67) 643 (24.20) 758 (30.56)
Renin-angiotensin inhibitor, n (%) 1841 (75.95) 1899 (76.63) 2144 (80.88) 2107 (85.06)
Antithrombotic agent or anticoagulant, n (%) 2314 (95.30) 2373 (95.53) 2513 (94.51) 2352 (94.84)
Median hsCRP level (IQR), mg/L 4.15 (2.75–7.10) 4.15 (2.80–7.10) 4.20 (2.80–6.95) 4.20 (2.85–7.00)
Median IL-6 level (IQR), ng/L 2.61 (1.77–4.21) 2.51 (1.77–4.04) 2.54 (1.77–4.04) 2.63 (1.83–4.13)
Median total cholesterol level (IQR), mg/dL 152.75 (131.00–181.36) 159.00 (136.00–187.16) 162.41 (138.00–193.00) 165.12 (139.98–194.00)
Median LDL cholesterol level (IQR), mg/dL 78.50 (60.00–101.70) 81.99 (63.42–106.00) 83.91 (64.97–109.82) 85.46 (66.90–110.60)
Median HDL cholesterol level (IQR), mg/dL 42.54 (35.96–51.00) 43.31 (36.35–51.04) 44.47 (37.51–53.00) 45.63 (38.00–54.14)
Median triglyceride level (IQR), mg/dL 134.00 (99.00–192.00) 140.00 (101.86–195.75) 142.60 (104.00–199.29) 138.18 (100.97–193.09)
Median estimated GFR(IQR), mL/min per 1.73 m2 79.00 (65.00–93.00) 80.00 (66.00–95.00) 79.00 (64.00–93.00) 76.00 (62.00–91.00)
BP indicates blood pressure; CABG, coronary artery bipass graft; GFR, glomerular filtration rate; HDL, high-density lipoprotein; hsCRP, high sensitivity C-reactive 
protein; IL, interleukin; IQR, interquartile range; LDL, low-density lipoprotein; Non-STEMI, non–ST-segment–elevation myocardial infarction; PCI, percutaneous 
coronary intervention; and STEMI, ST-segment–elevation myocardial infarction.
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with higher vascular risk during trial follow-up in both pla-
cebo and canakinumab groups. However, random allocation 
to canakinumab, a drug that inhibits IL-1β and reduces both 
IL-6 and hsCRP, did not reduce the development of incident 
hypertension nor reduce blood pressure at 3, 6, or 12 months.
In atherosclerotic mice, genetic deletion of IL-1 receptor 
19 can reduce blood pressure and administration of an IL-1β 
neutralizing antibody produces a dose-dependent reduction in 
lesion formation.11 In humans, a reduction in blood pressure 
accompanied a 14-day treatment with anakinra (an IL-1 re-
ceptor antagonist which inhibits both IL-1α and β) following 
acute coronary syndrome in post hoc analysis of the 182 in the 
Medical Research Council Interleukin-1 Receptor Antagonist 
Heart study.23–25 Yet, as reported here in 9549 CANTOS subjects, 
none of the 3 doses of canakinumab evaluated compared with 
placebo altered blood pressure at 3, 6, or 12 months. Potential 
explanations of these apparent differences include sample size, 
duration of follow-up, different approaches to IL-1 inhibition 
and distinct inclusion criteria. CANTOS enrolled patients with 
stable atherosclerosis and a prior myocardial infarction whereas 
MRC ILA Heart enrolled patients following an acute coronary 
syndrome. Perhaps most significantly a prior diagnosis of hy-
pertension and prior myocardial infarction was present in only 
30% and 24% of patients in MRC ILA Heart compared to 80% 
and 100% of patients in CANTOS, respectively. As such, the 
proportion of patients prescribed antihypertensive medication 
at baseline was higher in CANTOS.
In rats with angiotensin II–induced vascular injury and hy-
pertension, it has been shown that mycophenolate mofetil pre-
vents renal damage16 and interferon-γ targeting reduces cardiac 
arrhythmias and fibrosis without significant effects on blood 
pressure.26 As such, in patients with hypertension, anti-inflam-
matory therapy may provide benefit without blood pressure re-
duction. Consistent with previous literature and with clinical 
practice, absolute rates of adverse events in CANTOS increased 
with baseline systolic blood pressure in patients randomly allo-
cated to both canakinumab or placebo. As previously reported, 
the 150 mg dose of canakinumab reduced the risk of the com-
posite primary end point in CANTOS by 15% compared to pla-
cebo (3.86 versus 4.50 events per 100 person-years).17 Although 
not statistically significant, random allocation to canakinumab 
reduced the composite primary end point by 16% in patients 
with a baseline systolic blood pressure of 130 to 140 mm Hg 
(3.80 versus 4.54 events per 100 person-years) and 21% in 
patients with a baseline systolic blood pressure >140 mm Hg 
(4.43 versus 5.61 events per 100 person-years).
Strengths and Limitations
As a post hoc analysis of a randomized controlled trial, these 
data may be prone to type I error. Yet, despite our very large 
sample size, our analysis detected no interaction between 
canakinumab efficacy and blood pressure level nor any effect 
on measured blood pressure itself. This analysis was also 
Figure 1. Incident hypertension by tertile of baseline hsCRP (high 
sensitivity C-reactive protein; rate per 100-person years ± 95% CI, Cox 
proportional-hazard compared the time to diagnosis of incidence of 
hypertension and adjusted for age, sex, and body mass index, P>0.2).
Figure 2. Lack of effect of canakinumab 
compared to placebo on blood pressure. 
Office blood pressure of patients randomly 
allocated to canakinumab (50 mg, 150 mg, and 
canakinumab 300 mg) or placebo at baseline, 
3, 6, and 12 months (mean and 95% CI, upper: 
systolic blood pressure, lower: diastolic blood 
pressure.
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limited by the total number of cardiovascular events after strat-
ification by baseline systolic blood pressure, especially for less 
frequent outcomes such as stroke. By contrast, strengths of our 
study include its large sample size and consistency of results 
across follow-up timepoints and each dose of canakinumab.
Conclusions
While inhibition of IL-1β with canakinumab reduces cardi-
ovascular event rates, these analyses suggest that the mech-
anisms underlying this benefit are not related to changes in 
blood pressure or incident hypertension.
Perspectives
Hypertension and inflammation are physiologically inter-
related. Yet, the mechanisms through which inflammation 
and elevated blood pressure interact, and their causal rela-
tionships, remain uncertain. CANTOS afforded the unique 
opportunity to test whether IL-1β inhibition reduced blood 
pressure, prevented the development of incident hyper-
tension, or modified relationships between hypertension 
and cardiovascular events. While inhibition of IL-1β with 
canakinumab reduced cardiovascular event rates, these 
analyses suggest that the mechanisms underlying this ben-
efit are not related to changes in blood pressure or incident 
hypertension.
Sources of Funding
The investigator-driven CANTOS (Canakinumab Anti-inflammatory 
Thrombosis Outcomes Study) trial was funded by Novartis. A.M.K. 
Rothman and A. Webb are supported by Clinical Research Career 
Table 2. SBP and DBP at 3 Months in the Placebo Group and in the Combined Canakinumab Treatment Group Stratified by Achieved Levels of 
hsCRP and IL-6 Above or Below the On-Treatment Study Median
 Parameter N Median Lower Quartile Upper Quartile
hsCRP at 3 mo Placebo SBP at 3 mo 3116 129 120 140
DBP at 3 mo 3116 78 71 83
hsCRP ≥2.0 on 
canakinumab
SBP at 3 mo 2816 130 120 140
DBP at 3 mo 2816 78 71 84
hsCRP <2.0 on 
canakinumab
SBP at 3 mo 3438 129 120 140
DBP at 3 mo 3438 79 72 84
IL-6 at 3 mo Placebo SBP at 3 mo 1562 130 120 141
DBP at 3 mo 1562 78 71 83
IL-6 ≥1.65 on 
canakinumab
SBP at 3 mo 1587 130 120 141
DBP at 3 mo 1587 77 70 83
IL-6<1.65 on 
canakinumab
SBP at 3 mo 1593 130 120 141
DBP at 3 mo 1593 78 72 84
DBP indicates diastolic blood pressure; hsCRP, high sensitivity C-reactive protein; IL, interleukin; and SBP, systolic blood pressure.
Figure 3. The effect of canakinumab on 
clinical events stratified by baseline systolic 
blood pressure. Major adverse cardiovascular 
events (MACE), myocardial infarction, 
coronary revascularization, stroke, heart failure 
hospitalization, and mortality adjusted for 
age, sex, body mass index, LDL (low-density 
lipoprotein)-Cholesterol, and diabetes mellitus 
(placebo n=3344, canakinumab n=6717, 
number of events indicated by box size, hazard 
ratio indicated by box position with 95% CI, 
Q1: lowest baseline systolic blood pressure, 
Q4: highest baseline systolic blood pressure, 
<1 favors canakinumab). HR indicates hazard 
ratio.
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Development Fellowships from the Wellcome Trust (A.M.K. 
Rothman: 206632/Z/17/Z; A. Webb: 206589/Z/17/Z).
Disclosures
None.
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What Is New?
•	 In patients with prior myocardial infarction and persistent proinflam-
matory response: Canakinumab reduced cardiovascular events but not 
blood pressure or the rate of incident hypertension.
What Is Relevant?
•	 Inhibition of IL (interleukin)-1β does not alter blood pressure or incident 
hypertension.
Summary
While inhibition of IL-1β with canakinumab reduces cardiovascular 
event rates, the mechanisms are not related to changes in blood 
pressure or incident hypertension.
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